瑞舒伐他汀对冠心病合并慢性心力衰竭患者临床疗效及血浆脑钠肽的影响

目的观察瑞舒伐他汀对冠心病合并慢性心力衰竭患者（CHF）临床疗效及血浆脑钠肽（BNP）水平的影响。方法80例冠心病并CHF患者随机分为治疗组和对照组各40例，对照组患者给予抗心力衰竭的常规治疗；治疗组在对照组基础上加用瑞舒伐他汀钙治疗，每晚餐时服用20mg，1次／d。两组均治疗6个月。两组分别于治疗前及治疗6个月后测定左室心功能指标及血浆BNP水平。同时观察临床症状、体征及药物不良反应。结果治疗6个月后治疗组总有效率显著高于对照组（P〈0．05）；治疗组的心功能指标及血浆BNP水平的改善均优于对照组（P〈0．05，或P〈0．01）。结论CHF患者在常规治疗同时加用瑞舒伐他汀治疗，可以显著降低血浆BNP水平，改善心功能。

Effects of Rosuvastatin on patients with coronary heart disease complicated chronic heart failure on clinical and plasma brain natriuretic peptide levels

Objective To observe the effects of rosuvastatin on patients with coronayr heart disease complicated chronic heart failure (CHF) on with clinical and plasma brain natriuretic peptide (BNP) levels.Methods 80 patients with coronary heart disease were randomly divided into treatment group (40 cases) and control group (40 cases), the control group were treated with anti-heart failure of conventional treatment; the treatment group was added Rosuvastatin calcium treatment on the basis of the control group, each dinner taking 20mg, once a day, Both groups were treated for 6 months. The left ventricular cardiac function and plasma BNP levels were measured before treatment and after 6 months treatment. While observing the clinical symptoms,signs, and adverse drug reactions. Results After 6 months treatment the total effective rate of the treatment group was significantly higher than that of the control group (P<0.05); the indicators of cardiac function and plasma BNP levels improved compared with the control group (P<0.05, orP<0.01). Conclusion CHF patients increases with rosuvastatin treatment in the conventional treatment at the same time, can significantly reduce plasma BNP levels, improve heart function.